Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.
Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, Michigan Medicine researchers say.
Those two key problems – safety and efficacy – are what continue to hold CRISPR-Cas9 gene targeting back from its full clinical potential, explains co-senior author Y. Eugene Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry, from the Michigan Medicine Frankel Cardiovascular Center.
The new CRISPR-Cas9 variant improves efficiency when inserting a gene or DNA fragment to a precise location in the genome, known as knocking in. It also reduces the rate of unintended insertions or deletions, known as indels, of base pairs that often happen while gene editing.
“We name it meticulous integration Cas9, or miCas9, to reflect its extraordinary capacity to enable maximum integration, yet with minimal indels, as well as to recognize its development at the University of Michigan,” write senior authors Chen, Jifeng Zhang and Jie Xu for Nature’s “Behind the Paper” series. “It provides a ‘one small stone for three birds’ tool in gene editing.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
MiCas9
- Feed has no items.
Go deeper with Google Headlines on:
MiCas9
[google_news title=”” keyword=”miCas9″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CRISPR-Cas9
- Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
The potential affirmation of their CRISPR-Cas9 patent estate could act as another positive catalyst, potentially expanding licensing opportunities. Progress in their in vivo pipeline and a cash runway extending into 2026 also contribute to the Buy rating.
- CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing LNP mediated delivery to the liver for refractory hypertension targeting angiotensinogen (AGT) and acute hepatic porphyria (AHP) targeting 5’-aminolevulinate synthase 1 (ALAS1) - - CTX340™,
Go deeper with Google Headlines on:
CRISPR-Cas9
[google_news title=”” keyword=”CRISPR-Cas9″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]